PRTC

PureTech Health: Notice of Results

Retrieved on: 
목요일, 4월 18, 2024
Science, Other Science, Biotechnology, Research, General Health, Health, FDA, Clinical Trials, Account, PRTC, Annual report

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024.
  • A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations .

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Retrieved on: 
화요일, 4월 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Southern California, FDA, Idiopathic pulmonary fibrosis, University, Vital capacity, FVC, Safety, Survival, IPF, CNS, Incidence, Patient, TID, Pirfenidone, Caregiver, Aes, Central nervous system, PRTC, Biomarker, Pharmacology, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).
  • This PK profile and the resulting favorable tolerability have been demonstrated across multiple clinical trials in more than 400 individuals.
  • PureTech believes the results of the Phase 2b trial, together with an additional Phase 3 trial, could serve as the basis for registration in the U.S. and other geographies.
  • PureTech would like to extend its gratitude to those participating in the ELEVATE IPF trial, especially the people living with IPF and their caregivers, the clinical trial sites, investigators and advocacy groups.

PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

Retrieved on: 
목요일, 4월 11, 2024
Oncology, Health, FDA, Clinical Trials, Research, Science, Biotechnology, Cancer, Fast Track, Venetoclax, Food, Prognosis, Survival, AML, Bone marrow, Patient, Tislelizumab, Acute myeloid leukemia, PRTC, Head, Clinical trial, BeiGene, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas (“head and neck cancers”).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas (“head and neck cancers”).
  • It is being evaluated in two ongoing clinical trials:
    a Phase 1/2 adaptive design trial in advanced/metastatic solid tumors, including head and neck cancers.
  • “By granting Fast Track designation to LYT-200 for head and neck cancers, the FDA continues to highlight areas of critical need within oncology as well as the potential for LYT-200,” said Aleksandra Filipovic, M.D., Ph.D., Head of Oncology at PureTech.
  • The FDA has also granted orphan drug designation to LYT-200 for the treatment of AML .

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
화요일, 4월 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

PureTech Proposes $100 Million Capital Return

Retrieved on: 
화요일, 3월 19, 2024
Biotechnology, Pharmaceutical, Health, Schizophrenia, Patient, Share repurchase, Policy, Acquisition, PRTC, Tender offer, Therapy, Tender, Cryptocurrency

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces a proposed capital return of $100 million to its shareholders by way of a tender offer (the “Tender Offer”).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces a proposed capital return of $100 million to its shareholders by way of a tender offer (the “Tender Offer”).
  • The capital return of $100 million represents approximately 14% of PureTech’s market capitalization based on yesterday’s closing price.
  • This follows the Company’s announcement that it will receive approximately $293 million gross proceeds from its remaining stake in Karuna.
  • PureTech aims to maintain at least three year’s cash runway, and the Board intends to evaluate its capital allocation policy regularly to assess opportunities for additional capital returns to shareholders, subject to the Company’s operational needs.

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

Retrieved on: 
월요일, 3월 18, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Psychosis, Bristol Myers Squibb, Citigroup, Growth, Schizophrenia, KarXT, Goldman Sachs, EPS, Patient, Neuroscience, Simpson Thacher & Bartlett, Acquisition, BMS, LLP, PRTC, Therapy, GAAP, Covington & Burling, Psychiatry, Bipolar I disorder, PDUFA, Pharmaceutical industry

The full text of the announcement from Bristol Myers Squibb is as follows:

Key Points: 
  • The full text of the announcement from Bristol Myers Squibb is as follows:
    Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience
    PRINCETON, N.J.-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
  • With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).
  • “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia

Retrieved on: 
수요일, 3월 13, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, Head, Survival, Massachusetts General Hospital, AML, Patient, Doctor of Philosophy, MD, PRTC, HMA, Hospital, Bone marrow, MDS, Immunoglobulin G, Food, Person, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYT-200 for the treatment of AML.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYT-200 for the treatment of AML.
  • LYT-200 is a fully human IgG4 monoclonal antibody (mAb) targeting galectin-9, a potent oncogenic driver in leukemia cells and an immunosuppressive protein.
  • “Orphan drug designation from the FDA validates our belief that targeting galectin-9 with LYT-200 is a novel, promising approach that may offer patients a better tolerated, more effective treatment,” notes Aleksandra Filipovic, MD, PhD, Head of Oncology at PureTech.
  • The FDA grants orphan drug designation to novel drug and biologic products for the treatment, diagnosis, or prevention of conditions affecting fewer than 200,000 persons in the U.S. Orphan drug designation qualifies PureTech for incentives under the Orphan Drug Act, including tax credits for some clinical trials and eligibility for seven years of market exclusivity in the U.S., if the drug is approved for AML.

PureTech to Present at Two Upcoming Investor Conferences

Retrieved on: 
화요일, 2월 27, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, PRTC, Patient

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate at two upcoming investor conferences.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate at two upcoming investor conferences.
  • Webcasts of the presentations will be available at https://investors.puretechhealth.com .
  • Presenters: Daphne Zohar, Founder and Chief Executive Officer, and Eric Elenko, Ph.D., Chief Innovation Officer

PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan

Retrieved on: 
화요일, 2월 27, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Shionogi, Ministry, PRTC, Marketing, FDA, Food, Safety, Welfare, Patient, ADHD, Ageing, Pharmaceutical industry

"We are pleased by this additional validation of Akili’s EndeavorRx,” said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech.

Key Points: 
  • "We are pleased by this additional validation of Akili’s EndeavorRx,” said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech.
  • “The latest Japanese clinical trial of our patented, clinically proven technology is an important milestone for many reasons,” said Dr. Scott Kollins, Chief Medical Officer at Akili.
  • The trial aimed to evaluate the efficacy and safety of SDT-001 in 164 pediatric ADHD patients aged 6 to 17 who received conventional treatments such as environmental adjustments and psychosocial therapies.
  • Furthermore, symptom improvements were sustained even after two cycles of SDT-001 use, with no safety concerns noted.

FTC Selects CDG's OSS/BSS Platform to Evolve Their Subscriber Management

Retrieved on: 
월요일, 1월 29, 2024
CABS, CDG, OSS, BSS, Farmer, PRTC, OSS/BSS, Map, CIO, FTC, MBS, Mobile phone

FTC selects CDG's OSS/BSS platform to evolve their subscriber management.

Key Points: 
  • FTC selects CDG's OSS/BSS platform to evolve their subscriber management.
  • In making this announcement, CDG and PRTC CEO, Jason Dandridge, noted "I can't tell you how special it is to have FTC join our MBS family.
  • FTC is a long-term client of CDG's carrier services solution, BDS-I, and FTC and PRTC also go way back as neighboring South Carolina telecommunications service providers.
  • CDG is excited to partner with FTC to help them evolve their subscriber management experience."